HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Yasser Emad Selected Research

Antirheumatic Agents (DMARD)

9/2008Enhanced MRI in early undifferentiated oligoarthritis of the knee joints: improvements already visible after 2 months of DMARDs treatment.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Yasser Emad Research Topics

Disease

4Thrombosis (Thrombus)
09/2023 - 04/2020
4Vasculitis (Vasculitides)
09/2023 - 04/2020
4Inflammation (Inflammations)
02/2022 - 11/2015
3Aneurysm (Aneurysms)
09/2023 - 04/2020
3Osteoporosis
09/2022 - 11/2012
3Rheumatoid Arthritis
05/2021 - 08/2010
3Arthritis (Polyarthritis)
06/2014 - 09/2008
2Venous Thrombosis (Deep-Vein Thrombosis)
09/2023 - 04/2020
2Synovitis
09/2022 - 09/2008
2Edema (Dropsy)
09/2021 - 09/2008
2Juvenile Arthritis (Juvenile Idiopathic Arthritis)
01/2013 - 05/2012
1False Aneurysm (Pseudoaneurysm)
09/2023
1Actinomycosis
11/2022
1Rupture
12/2021
1Hemoptysis
01/2021
1Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
07/2020
1Microscopic Polyangiitis
07/2020
1Granulomatosis with Polyangiitis (Wegener's Granulomatosis)
07/2020
1Churg-Strauss Syndrome (Allergic Angiitis)
07/2020
1Pulmonary Embolism
04/2020
1Vascular Calcification
04/2018
1Systemic Scleroderma (Systemic Sclerosis)
04/2018
1Atherosclerosis
04/2018
1Gouty Arthritis
11/2015
1Tenosynovitis
11/2015
1Rheumatic Diseases (Rheumatism)
06/2014
1Palindromic rheumatism
06/2014
1Pain (Aches)
11/2012
1Lichen Planus (Lichen Ruber Planus)
06/2012
1Adult-Onset Still's Disease
06/2012
1Lupus Nephritis
10/2011
1Systemic Lupus Erythematosus (Libman-Sacks Disease)
10/2011
1Fibromyalgia (Fibrositis)
07/2008

Drug/Important Bio-Agent (IBA)

44- ((1,4,8,11- tetraazacyclotetradec- 1- yl)methyl)benzoic acidIBA
09/2023 - 04/2020
4Biomarkers (Surrogate Marker)IBA
02/2022 - 10/2011
3AntibodiesIBA
06/2014 - 08/2010
3Anti-Citrullinated Protein AntibodiesIBA
06/2014 - 08/2010
2GadoliniumIBA
09/2022 - 11/2015
2Leukocyte L1 Antigen Complex (Calgranulin)IBA
02/2022 - 11/2020
2Alendronate (Alendronate Sodium)FDA LinkGeneric
09/2021 - 11/2012
2Mycophenolic Acid (Cellcept)FDA LinkGeneric
07/2020 - 06/2012
2LigandsIBA
04/2018 - 05/2012
2OsteoprotegerinIBA
04/2018 - 10/2011
2cyclic citrullinated peptideIBA
06/2014 - 01/2013
2Hydroxychloroquine (Plaquenil)FDA LinkGeneric
06/2014 - 09/2008
1Nuclear Antigens (Extractable Nuclear Antigens)IBA
05/2021
1AutoantibodiesIBA
05/2021
1Antineutrophil Cytoplasmic Antibodies (ANCA)IBA
07/2020
1Immunologic Factors (Immunomodulators)IBA
04/2020
1Indicators and Reagents (Reagents)IBA
04/2018
1LipidsIBA
04/2018
1Uric Acid (Urate)IBA
11/2015
1Rheumatoid FactorIBA
06/2014
1Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
05/2012
1B-Cell Activating FactorIBA
05/2012
1Chemokine CCL2 (Monocyte Chemoattractant Protein 1)IBA
10/2011
1Interleukin-8 (Interleukin 8)IBA
10/2011
1Proteins (Proteins, Gene)FDA Link
08/2010
1Methotrexate (Mexate)FDA LinkGeneric
09/2008
1Antirheumatic Agents (DMARD)IBA
09/2008
1Protons (Proton)IBA
07/2008

Therapy/Procedure

3Aftercare (After-Treatment)
09/2021 - 09/2008
1Intrauterine Devices (Intrauterine Device)
11/2022
1Therapeutics
09/2021